Skip to main content

Leonard Braden Michael's Form 4 filing

OnKure Therapeutics, Inc. (OKUR) · filed Sep 19, 2024

Accession no.
0001373604-24-000094
Filed
Sep 19, 2024
Trade date
Sep 17-18, 2024
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market purchases total $76.3K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Leonard Braden MichaelCIK 000137360310% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 17, 2024Common StockPPurchaseAcquired+55,300$1.36F2+$75,2083,358,243Indirect
Sep 18, 2024Common StockPPurchaseAcquired+806$1.40F3+$1,128.43,359,049Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Purchased in multiple transactions with a weighted average price of $1.3582. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

Referenced by the price of 1 transaction in Table I.

F3

Purchased in multiple transactions with a weighted average price of $1.40. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)